Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Perspective Therapeutics, Inc. (NYSE: CATX) had its price target lowered by analysts at Royal Bank of Canada from $25.00 to $16.00. They now have an "outperform" rating on the stock.
Perspective Therapeutics, Inc. (NYSE: CATX) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $5.00 price target on the stock, down previously from $24.00.
Perspective Therapeutics, Inc. (NYSE: CATX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $22.00 to $16.00. They now have an "outperform" rating on the stock.
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, down previously from $20.00.